Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-11-18 | New | $618,000 | $618,000 | Debt Only | 06b | SEC link |
| 2025-02-04 | Amended | $7,710,767 | $2,247,528 | Equity Only | 06b | SEC link |
| 2024-12-10 | Amended | $5,463,239 | $977,375 | Equity Only | 06b | SEC link |
| 2024-03-05 | Amended | $4,485,864 | $802,578 | Equity Only | 06b | SEC link |
| 2023-05-25 | New | $3,683,286 | $3,683,286 | Equity Only | 06b | SEC link |
| 2020-05-22 | New | $835,000 | $835,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Robert Crutchfield | Director |
| Mark Deem | Director |
| Martin L. Mayse | Director, Executive, Promoter |
| Amy Salzhauer | Director |
| Richard Stark | Director |
| Gintaras Vaisnys | Director |